Impact of metformin therapy on health-related quality of life outcomes in tuberculosis patients with diabetes mellitus in India: A prospective study.
diabetes
drug repositioning
health-related quality of life
metformin
tuberculosis
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
revised:
02
09
2020
received:
17
06
2020
accepted:
18
11
2020
pubmed:
26
11
2020
medline:
28
4
2021
entrez:
25
11
2020
Statut:
ppublish
Résumé
To assess the impact of metformin use on health-related quality of life (HRQoL) in tuberculosis (TB) patients who are presented with type 2 diabetes mellitus (T2DM). In this community-based prospective study, TB patients attending Hakeem Abdul Hameed Centenary Hospital, New Delhi (India) and had comorbidity of T2DM between April 2018 and July 2019 were enrolled. Patients were divided into metformin users and metformin non-users on the basis of the presence of metformin in their routine as antidiabetic drug(s). HRQoL was determined using a validated TB-specific tool (Dhingra and Rajpal-12 scale ie, DR-12) consists of symptom and socio-psychological and exercise adaptation domains. The HRQoL scores were compared at pretreatment (1st visit), end of intensive phase (2nd visit) and end of treatment (3rd visit) between the two groups. A total of 120 patients were enrolled, of which 24 were excluded as they did not respond at follow-up visits. Among the metformin users (n = 48) the mean age of patients was 47.56 years and 62.50% was males. Among the metformin non-users (n = 48), the mean age of patients was 49.02 years and 54.10% was males. The baseline characteristics were similar in both groups except for the substance used history (P = .025), literacy level (P = .048) and BMI (P = .028). Metformin users demonstrated significant improvement in symptom scores (2nd visit: P < .001; 3rd visit: P = .001) and socio-psychological and exercise adaptation scores (2nd visit: P < .0001; 3rd visit: P < .0001) as compared with metformin non-users at 2nd visit and 3rd visit. Overall, scores were also found to be significantly improved in metformin users (2nd visit: P < .001; 3rd visit: P = .001). Metformin therapy exerted favourable effects on HRQoL in patients with TB and T2DM and can be recommended as an adjuvant antitubercular drug in TB patients with co-morbidity of T2DM, unless contraindicated.
Substances chimiques
Hypoglycemic Agents
0
Metformin
9100L32L2N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13864Subventions
Organisme : Department of Science and Technology, Philippines
ID : IF-160196
Organisme : Department of Science and Technology, India
ID : IF-160196
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Zwerling A, Hanrahan C, Dowdy DW. Ancient disease, modern epidemiology: a century of progress in understanding and fighting tuberculosis. Am J Epidemiol. 2016;183:407-414.
WHO Global Tuberculosis Report 2019. United Nations: World Health organization, 2019.
Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2019;1:107843.
Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9:737-746.
Harries AD, Satyanarayana S, Kumar AMV, et al. Epidemiology and interaction of diabetes mellitus and tuberculosis and challenges for care: a review. Public Health Action. 2013;3(Suppl 1):S3-S9.
Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008;5:e152.
Zumla AI, Gillespie SH, Hoelscher M, et al. New antituberculosis drugs regimens and adjunct therapies need advances and future prospects. Lancet Infect Dis. 2014;14:327-340.
Padampriydarshini C, Bhavani PK, Natrajan M, et al. Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial. BMJ Open. 2019;9:e024363.
Mishra R, Krishan S, Siddiqui AN, Kapur P, Khayyam KU, Sharma M. Potential role of adjuvant drugs on efficacy of first line oral antitubercular therapy: drug repurposing. Tuberculosis. 2020;11:101902.
Marupuru S, Senapati P, Pathadka S, Miraj SS, Unnikrishnan MK, Manu K. Protective effect of metformin against tuberculosis infections in diabetic patients: an observational study of south Indian tertiary health care facility. Braz J Infect Dis. 2017;21:312-316.
Singhal A, Jie L, Kumar P, et al. Metformin as adjunct antituberculosis therapy. Sci Transl Med. 2014;6:59.
Brown J, Capocci S, Smith C, Morris S, Abubakar I, Lipman M. Health status and quality of life in tuberculosis. Int J Infect Dis. 2015;1:68-75.
Li CT, Chu KH, Reiher B, Kienene T, Chien LY. Evaluation of health-related quality of life in patients with tuberculosis who completed treatment in Kiribati. J Int Med Res. 2017;45:610-620.
Siddiqui AN, Khayyam KU, Siddiqui N, Sarin R, Sharma M. Diabetes prevalence and its impact on health-related quality of life in tuberculosis patients. Trop Med Int Health. 2017;22:1394-1404.
Malik M, Nasir R, Hussain A. Health related quality of life among TB Patients: question mark on performance of TB DOTS in Pakistan. J Trop Med. 2018;2018:1-7.
Conversano C. Psychological common factors in chronic diseases. Front Psychol. 2019;10:2727.
Martino G, Caputo A, Bellone F, Quattropani MC, Vicario CM. Going beyond the visible in type 2 diabetes mellitus: defense mechanisms and their associations with depression and health-related quality of life. Front Psychol. 2020;11:267.
Martino G, Langher V, Cazzato V, Vicario CM. Psychological factors as determinants of medical conditions. Front Psychol. 2019;10:2502.
Merlo EM. Opinion article: the role of psychological features in chronic diseases, advancements and perspectives. Mediterr J Clin Psychol. 2019;7.
Dhingra VK, Rajpal S. Health related quality of life (HRQL) scoring (DR-12 score) in tuberculosis-additional evaluative tool under DOTS. J Commun Dis. 2005;37:261-268.
ADA. Standards of medical care in diabetes-2015: summary of revisions. Diabetes Care. 2015;38(Suppl):S4.
Bairwa M, Rajput M, Sachdeva S. Modified Kuppuswamy’s socioeconomic scale: social researcher should include updated income criteria, 2012. Indian J Community Med. 2013;38:185.
Dujaili JA, Sulaiman SA, Hassali MA, Awaisu A, Blebil AQ, Bredle JM. Health-related quality of life as a predictor of tuberculosis treatment outcomes in Iraq. Int J Infect Dis. 2015;1:4-8.
Patel AE, Lalitha K, Rajaram D, Radhika K, Murthy NS. Quality of life among patients on MDR-TB treatment in a district tuberculosis centre of a metropolitan city. Int J Community Med. Public Health. 2018;5:5355-5359.
Salehitali S, Noorian K, Hafizi M, Dehkordi AH. Quality of life and its effective factors in tuberculosis patients receiving directly observed treatment short-course (DOTS). J Clin Tuberc Other Mycobact Dis. 2019;1:100093.
Patel AE, Lalitha K, Rajaram D, Radhika K, Murthy NS. Quality of life among patients on MDR-TB treatment in a district tuberculosis centre of a metropolitan city. Int J Commun Med Public Health. 2018;5:5355-5359.
Lee YJ, Han SK, Park JH, et al. The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus. Korean J Intern Med. 2018;33:933.
Chikaodinaka AA. Health-Related Quality of Life (HRQoL) scores vary with treatment and may identify potential defaulters during treatment of tuberculosis. Malawi Med J. 2018;30:283-290.
Kastien-Hilka T, Abulfathi A, Rosenkranz B, Bennett B, Schwenkglenks M, Sinanovic E. Health-related quality of life and its association with medication adherence in active pulmonary tuberculosis-a systematic review of global literature with focus on South Africa. Health Qual Life Outcomes. 2016;14:42.
Singh J, Kajal NC, Singh M, Verma V. Health related quality of life scoring in tuberculosis. Chest. 2004;126(4):833S.
Dhuria M, Singh NP, Jiloha RC, Saha R, Ingle GK. A study of the impact of tuberculosis on the quality of life and the effect after treatment with DOTS. Asia Pac J Public Health. 2009;21:312-320.
Marra CA, Marra F, Colley L, Moadebi S, Elwood RK, Fitzgerald JM. Health-related quality of life trajectories among adults with tuberculosis: differences between latent and active infection. Chest. 2008;133:396-403.
Othman GQ, Ibrahim MI, Rajaa YA. Health related quality of life of pulmonary and extrapulmonary tuberculosis patients in Yemen. Afr J Pharm Pharmacol. 2011;5:547-553
Chamla D. The assessment of patients' health related quality of life during tuberculosis treatment in Wuhan, China. Int J Tuberc Lung Dis. 2004;8:1100-1106.
Yew WW, Chang KC, Chan DP, Zhang Y. Metformin as a host-directed therapeutic in tuberculosis: Is there a promise? Tuberculosis. 2019;115:76-80.
Vashisht R, Brahmachari SK. Metformin as a potential combination therapy with existing front-line antibiotics for tuberculosis. J Transl Med. 2015;7:83.
Tseng CH. Metformin decreases risk of tuberculosis infection in type 2 diabetes patients. J Clin Med. 2018;7:264.
Lachmandas E, Eckold C, Böhme J, et al. Metformin alters human host responses to Mycobacterium tuberculosis in healthy subjects. J of infect dis. 2019;220:139-150.
Dudzińska M, Kurowska M, Tarach JS, Chitryń A, Wdowiak-Barton B. Social problems of diabetics. The influence of diabetes on patients’ daily, family and personal lives. Diabetologia Doświadczalna i Kliniczna. 2008;8:150-249.
Lau CY, Qureshi AK, Scott SG. Association between glycaemic control and quality of life in diabetes mellitus. J Postgrad Med. 2004;50: 189-193; discussion 94.
Engström MS, Leksell J, Johansson UB, et al. Health-related quality of life and glycaemic control among adults with type 1 and type 2 diabetes-a nationwide cross-sectional study. Health Quality Life Outcomes. 2019;17:141.
Wang JY, Lee LN, Hsueh PR. Factors changing the manifestation of pulmonary tuberculosis. Int J Tuberc Lung Dis. 2005;9:777-783.
Lecube A, Pachón G, Petriz J, Hernández C, Simó R. Phagocytic activity is impaired in type 2 diabetes mellitus and increases after metabolic improvement. PLoS One. 2011;6:e23366.
Khanna A, Bush AL, Swint JM, Peskin MF, Street RL, Naik AD. Hemoglobin a 1c improvements and better diabetes-specific quality of life among participants completing diabetes self-management programs: a nested cohort study. Health Qual Life Outcomes. 2012;10:48.
Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ. Quantifying the effect of metformin treatment and dose on glycaemic control. Diabetes Care. 2012;35:446-454.